Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
RESEARCH TOOLSreports
Barinthus Biotherapeutics (BRNS) Stock Price & Analysis
72 Followers
BRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.64 - $5.10
Previous Close$2.05
Volume12.26K
Average Volume (3M)25.09K
Market Cap
$101.32M
Enterprise Value-$49.68M
Total Cash (Recent Filing)$142.09M
Total Debt (Recent Filing)$12.98M
Price to Earnings (P/E)N/A
Beta0.68
Next Earnings
May 09, 2024EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding38,921,212
10 Day Avg. Volume24,207
30 Day Avg. Volume25,090
Standard Deviation0.19
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.84
Enterprise Value/Gross Profit-61.95
Enterprise Value/Ebitda0.82
Forecast
1Y Price Target
$7.50Price Target Upside248.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Barinthus Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAPOLLO trial of VTP-200 met safety endpoint; preliminary efficacy observed.
Financial HealthThe company had $142.1M in cash, which could provide an operational runway.
Product PipelineVTP-300 and nivolumab combo therapy show sustained HBsAg reductions.
Bears Say
Analyst ValuationThe 12-month price target for the stock has been lowered to $8 from $15.
Clinical TrialsRisks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.
Financial PerformanceNet loss totaled $73.3M.
---
Ownership Overview
40.01% Insiders
0.03% Mutual Funds
0.06% Other Institutional Investors
59.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $1.64 and its highest was $5.10 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Currently, no data Available
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is May 09, 2024 which is in 6 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Mar 20, 2024. The company reported -$0.449 earnings per share for the quarter, beating the consensus estimate of -$0.499 by $0.05.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -$0.54.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 38,546,593 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.449 in its last earnings report, beating expectations of -$0.499. Following the earnings report the stock price went up 1.66%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
---
Barinthus Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (248.84% Upside)
$7.50 (248.84% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.25%
12-Months-Change
Fundamentals
Return on Equity
-34.28%
Trailing 12-Months
Asset Growth
-19.15%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics
Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca.
---
BRNS Stock 12 Months Forecast
Average Price Target
$7.50
▲(248.84% Upside)
Technical Analysis
Best Analysts Covering BRNS
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-23.66%
reiterated a buy rating 15 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -23.66% per trade.
---